This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
AxoGen, Inc. (OTCBB: AXGN) today announced that it will release its financial results for the third quarter ended September 30, 2011, after the close of U.S. financial markets on November 9, 2011. An accompanying conference call hosted by Karen Zaderej, Chief Executive Officer, and Greg Freitag, Chief Financial Officer, to discuss the results will be held at 3:00 p.m. ET, on November 10, 2011.
An audio replay of the conference call will be available from 6:00 p.m. ET on November 10, 2011, through 6:00 p.m. ET on November 17, 2011 by dialing 888.203.1112 from the U.S. or 719.457.0820 from abroad. The audio webcast will also be available on the company's website, www.axogeninc.com, for one year.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance
® Nerve Graft, which AxoGen believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). AxoGen’s portfolio also includes AxoGuard
® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard
® Nerve Protector that protects nerves during the body’s healing process after surgery. AxoGen is bringing the science of nerve repair to life with over 6,000 surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.
AxoGen (formerly known as LecTec Corporation) is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.